CELLY NUTRITION ANNOUCES APPOINTMENT OF NEW DIRECTOR AND EQUITY INCENTIVE COMPENSATION GRANTS
TORONTO, ONTARIO, CANADA, October 20, 2023 /EINPresswire.com/ -- Celly Nutrition Corp. (formerly, 1319741 B.C. Ltd.) (the “Company” or “Celly”) is pleased to announce that Eric Hoskins has been appointed as an independent member of the board of directors of the Company (the "Board').
“I am very pleased to welcome Dr. Hoskins to our Board,” said Gerard David, director of the Company. “Dr. Hoskins is a medical doctor with a PhD in Community Medicine (Public Health) from Oxford University (as a Rhodes scholar) and has spent nearly four decades in the health care sector. An Officer of the Order of Canada, Dr. Hoskins has worked in health systems in Canada and around the world. He was Ontario’s former Minister of Health (2014-18), Minister of Economic Development and Trade (2012-14), Minister of Children and Youth Services (2011-13) and Minister of Citizenship and Immigration (2010-11). In 2018-19, Dr. Hoskins was the Chair of the Federal Advisory Council on the Implementation of National Pharmacare. Co-founder of the charity War Child, Dr. Hoskins has many years of experience creating and delivering humanitarian and development programs in war zones in Africa and the Middle East. Dr. Hoskins is a strong negotiator and navigator at the highest levels of government in Canada and around the world. He has a sound knowledge of health policy and the regulatory environment at both provincial and federal levels of government. Dr. Hoskins serves on a number of public and private medical technology and health-focused boards.”
In connection with Dr. Hoskins’s board appointment, the Company has granted 3,000,000 Options and 10,000,000 Restricted Share Units to Dr. Hoskins pursuant to its Equity Incentive Plan adopted and ratified by the Company’s shareholders by written consent on September 5, 2023. All securities issued will be subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance.
For further information:
John Duffy
Chief Executive Officer
T: (508) 479-4923
E: johnduffy@cellynutrition.com
About Celly Nutrition Corp.:
The Company is an unlisted reporting issuer in the provinces of British Columbia and Alberta with no current activities or operations.
Cautionary Statement Regarding Forward Looking Information
This press release contains “forward-looking information” within the meaning of applicable Cana-dian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the future Option and Restricted Stock Units grants made pursuant to the terms and conditions of the Equity Incentive Plan.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; and the Company granting future Options and Restricted Stock Units pursuant to the terms and conditions of the Equity Incentive Plan.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; and risks of the dilution to Common Shares and any other adverse risks resulting from the adoption of the Equity Incentive Plan and issuance of awards thereunder.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
“I am very pleased to welcome Dr. Hoskins to our Board,” said Gerard David, director of the Company. “Dr. Hoskins is a medical doctor with a PhD in Community Medicine (Public Health) from Oxford University (as a Rhodes scholar) and has spent nearly four decades in the health care sector. An Officer of the Order of Canada, Dr. Hoskins has worked in health systems in Canada and around the world. He was Ontario’s former Minister of Health (2014-18), Minister of Economic Development and Trade (2012-14), Minister of Children and Youth Services (2011-13) and Minister of Citizenship and Immigration (2010-11). In 2018-19, Dr. Hoskins was the Chair of the Federal Advisory Council on the Implementation of National Pharmacare. Co-founder of the charity War Child, Dr. Hoskins has many years of experience creating and delivering humanitarian and development programs in war zones in Africa and the Middle East. Dr. Hoskins is a strong negotiator and navigator at the highest levels of government in Canada and around the world. He has a sound knowledge of health policy and the regulatory environment at both provincial and federal levels of government. Dr. Hoskins serves on a number of public and private medical technology and health-focused boards.”
In connection with Dr. Hoskins’s board appointment, the Company has granted 3,000,000 Options and 10,000,000 Restricted Share Units to Dr. Hoskins pursuant to its Equity Incentive Plan adopted and ratified by the Company’s shareholders by written consent on September 5, 2023. All securities issued will be subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance.
For further information:
John Duffy
Chief Executive Officer
T: (508) 479-4923
E: johnduffy@cellynutrition.com
About Celly Nutrition Corp.:
The Company is an unlisted reporting issuer in the provinces of British Columbia and Alberta with no current activities or operations.
Cautionary Statement Regarding Forward Looking Information
This press release contains “forward-looking information” within the meaning of applicable Cana-dian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the future Option and Restricted Stock Units grants made pursuant to the terms and conditions of the Equity Incentive Plan.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; and the Company granting future Options and Restricted Stock Units pursuant to the terms and conditions of the Equity Incentive Plan.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; and risks of the dilution to Common Shares and any other adverse risks resulting from the adoption of the Equity Incentive Plan and issuance of awards thereunder.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
John Duffy
Celly Nutrition Corp.
+1 508-479-4923
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.